Natera Ends Suit Over Inivata Cancer Test After Key Patent Nixed

Natera Inc. dropped part of its patent-infringement dispute with Inivata Ltd. in Delaware federal court, ending claims over Inivata’s RaDaR cancer-detection test while earlier allegations involving a lung-cancer test proceed.

The voluntary dismissal without prejudice ends Natera’s 2022 lawsuit accusing the NeoGenomics Inc. unit’s RaDaR test of infringing US Patent No. 11,530,454, which covers methods for sequencing and analyzing cell-free DNA, according to Natera’s notice filed Oct. 17 in the US District Court for the District of Delaware.

• The move followed an Aug. 28 ruling by a North Carolina federal judge invalidating that patent and a related one.
• Natera ...